Since both tissue and blood-based NRP-1 levels allow for prognostic stratification in ovarian cancer (16), further investigation should aim to investigate 1) the cellular processing of NRP-1, 2) its release from the tumor microenvironment in patients with ovarian cancer, and 3) determinants of its concentration in non-malignant physiological conditions. This evidence concerns the gene NRP1 and ovarian cancer.